Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 3Rhabdomyosarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Leukemia, Biphenotypic, Acute 2Sarcoma, Myeloid 1Sarcoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1PRETEXT I Hepatoblastoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Malignant mesenchymal tumor 1Ganglioneuroblastoma 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Watchful Waiting 1Vincristine 1Topotecan 1Specimen Handling 1Razoxane 1Observation 1Magnetic Resonance Spectroscopy 1Ifosfamide 1High-Energy Shock Waves 1Doxorubicin 1Dexrazoxane 1Dactinomycin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pleuropulmonary blastoma × Dexrazoxane × 90 days × Clear all
NCT06647953 2026-05-05

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Children's Oncology Group

Phase 3 Recruiting
110 enrolled

Pleuropulmonary blastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡